Nectin Therapeutics Overview
Nectin Therapeutics is a biotechnology company devoted to transforming the lives of cancer patients by the development of next-generation immune-oncology (IO) therapies. The company is dedicated to the development of novel therapeutic options for cancer patients. It is developing a diverse pipeline of targeted antibodies based on the nectin pathways. These antibodies overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, it develops CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers. The company was established based on seminal research at the Hebrew University of Jerusalem and the University of Rijeka. Its technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody-drug-conjugates.
Cumulative Funding Raised Over Time ($)
$13.6MDec 2022
$14.6MJan 2017
$20.6MJul 2020
$26.0MMar 2022
$26.0MMay 2023
$36.0MMay 2024
Latest News
growth-positive
Israeli biotech co Nectin Therapeutics raises $10m
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Israeli biotechnology company Nectin Therapeutics. Nectin is developing targeted immunotherapies for resistance to approved immune oncology treatments. The investment will be used to continue the development of Nectins portfolio of novel immuno-oncology products, including the advancement of Nectins ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio.
Investment
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
growth-positive
Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace
Nectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of its novel anti-PVR antibody, NTX1088, in combination with Mercks anti-PD1 therapy, KEYTRUDA, in patients with solid tumors. NTX1088 aims to restore the antitumor immune activity of DNAM1 by blocking PVR, a protein associated with resistance to immune checkpoint inhibitors. The phase 1 trial with NTX1088 has already been initiated. The collaboration represents a promising new therapy for cancer patients and a milestone for Nectin Therapeutics.
Partners
growth-positive
Israeli co Nectin Therapeutics raises $25m
Nectin Therapeutics, an Israeli biotechnology company, has completed a $25 million Series A financing round led by IBF and Peregrine Ventures. The funding will be used to support the ongoing clinical evaluation of NTX1088, the companys first-in-class PVR (CD155) blocker, and to further advance its pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company has also announced the dosing of the first patient in its Phase I clinical trial of NTX1088, which is being conducted at The University of Texas MD Anderson Cancer Center. Nectin aims to overcome the limitations of existing IO therapies and provide new treatment options for patients with difficult-to-treat cancers.
InvestmentExpand
growth-positive
Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Nectin Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial of NTX1088, a first-in-class PVR (CD155) blocker for cancer patients with advanced solid tumors. The trial is being conducted at MD Anderson Cancer Center with an investment from the Cancer Focus Fund. Nectin has also extended its Series A financing to over $25 million, with IBF and Peregrine Ventures leading the round. The funding will be used to support the ongoing clinical evaluation of NTX1088 and advance the companys pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). NTX1088 aims to restore DNAM-1 expression on immune cells and stimulate an anti-tumor immune response. PVR is overexpressed in many solid tumors and is associated with resistance to PD-1 and PD-L1 blockade. The Phase 1 trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.
InvestmentExpand
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $36M |
| Last funding | $10M |
| Stage | A |
| Rounds | 6 |
| Investors | 7 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | www.nectintx.com |
Locations
Givat Ram, Jerusalem, Israel
1 Bridge Plaza North, Fort Lee, NJ, USA
Photos & Videos
1 item(s)
Nectin Therapeutics Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsCore Technology
BiologicalsCellsTags (10)
biotechnologypharmaceuticalsoncologyimmunologycancer-therapycancerantibodiespatientsdrug-deliverytreatmentsNectin Therapeutics Financials
$36M
Total funding
Undisclosed
Capital raised
$10M
Last funding
A
Funding stage
6
Total rounds
7
Investors
Cumulative Funding Raised Over Time ($)
$13.6MDec 2022
$14.6MJan 2017
$20.6MJul 2020
$26.0MMar 2022
$26.0MMay 2023
$36.0MMay 2024
Private Equity Funding
A Round
May 2024
$10M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
Undisclosed Round
May 2023
Undisclosed
Myeloma Investment Fund (Lead)
A Round
Dec 2022
$13.6M
Peregrine Ventures (Lead), Israel Biotech Fund (Lead)
,
aMoon Fund
A Round
Mar 2022
$5.4M
Cancer Focus Fund
A Round
Jul 2020
$6M
aMoon Fund (Lead)
,
Integra Holdings
Seed
Jan 2017
$1M
Integra Holdings
Nectin Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$13.6MDec 2022
$14.6MJan 2017
$20.6MJul 2020
$26.0MMar 2022
$26.0MMay 2023
$36.0MMay 2024
All Events
A Round
May 2024
$10M
Guangzhou Sino-Israel Biotech Investment Fund (GIBF) (Lead)
Undisclosed Round
May 2023
Undisclosed
Myeloma Investment Fund (Lead)
A Round
Dec 2022
$13.6M
Peregrine Ventures (Lead), Israel Biotech Fund (Lead)
,
aMoon Fund
A Round
Mar 2022
$5.4M
Cancer Focus Fund
A Round
Jul 2020
$6M
aMoon Fund (Lead)
,
Integra Holdings
Seed
Jan 2017
$1M
Integra Holdings
Nectin Therapeutics News
7 articles
growth-positive
Israeli biotech co Nectin Therapeutics raises $10m
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Israeli biotechnology company Nectin Therapeutics. Nectin is developing targeted immunotherapies for resistance to approved immune oncology treatments. The investment will be used to continue the development of Nectins portfolio of novel immuno-oncology products, including the advancement of Nectins ongoing NTX1088 global Phase 1 clinical trial targeting PVR and the preclinical development of its anti-drug conjugate (ADC) portfolio.
Investment
Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin's Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma
growth-positive
Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Locally Advanced and Metastatic Solid Tumors | BioSpace
Nectin Therapeutics has entered into a clinical trial collaboration agreement with Merck to evaluate the safety and efficacy of its novel anti-PVR antibody, NTX1088, in combination with Mercks anti-PD1 therapy, KEYTRUDA, in patients with solid tumors. NTX1088 aims to restore the antitumor immune activity of DNAM1 by blocking PVR, a protein associated with resistance to immune checkpoint inhibitors. The phase 1 trial with NTX1088 has already been initiated. The collaboration represents a promising new therapy for cancer patients and a milestone for Nectin Therapeutics.
Partners
growth-positive
Israeli co Nectin Therapeutics raises $25m
Nectin Therapeutics, an Israeli biotechnology company, has completed a $25 million Series A financing round led by IBF and Peregrine Ventures. The funding will be used to support the ongoing clinical evaluation of NTX1088, the companys first-in-class PVR (CD155) blocker, and to further advance its pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). Nectin is developing novel targeted immunotherapies to address resistance to approved immuno-oncology treatments. The company has also announced the dosing of the first patient in its Phase I clinical trial of NTX1088, which is being conducted at The University of Texas MD Anderson Cancer Center. Nectin aims to overcome the limitations of existing IO therapies and provide new treatment options for patients with difficult-to-treat cancers.
InvestmentExpand
growth-positive
Nectin Therapeutics Announces Initiation of Patient Dosing in Phase 1 Clinical Trial of NTX1088, First-in-Class Anti-PVR Targeted Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Nectin Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial of NTX1088, a first-in-class PVR (CD155) blocker for cancer patients with advanced solid tumors. The trial is being conducted at MD Anderson Cancer Center with an investment from the Cancer Focus Fund. Nectin has also extended its Series A financing to over $25 million, with IBF and Peregrine Ventures leading the round. The funding will be used to support the ongoing clinical evaluation of NTX1088 and advance the companys pipeline of targeted immunotherapies and Antibody Drug Conjugates (ADCs). NTX1088 aims to restore DNAM-1 expression on immune cells and stimulate an anti-tumor immune response. PVR is overexpressed in many solid tumors and is associated with resistance to PD-1 and PD-L1 blockade. The Phase 1 trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.
InvestmentExpand
growth-positive
Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy
Nectin Therapeutics and Cancer Focus Fund have announced a $5.4 million investment to finance a Phase 1 clinical trial of Nectins PVR blocker, NTX1088, in cancer patients with locally advanced and metastatic solid tumors. NTX1088 is a monoclonal antibody that blocks the signaling of immune checkpoint receptors, resulting in increased anti-tumor immune effects. The investment will support the clinical study at MD Anderson, and Cancer Focus Fund will receive equity and future payments based on certain milestones. The Phase 1 trial is expected to begin enrolling patients in mid-2022.
Investment
growth-positive
Israeli immuno-oncology co Nectin raises $6m
Nectin Therapeutics, an Israeli immuno-oncology biotherapies company, has completed the first $6 million closing of a financing round led by aMoon Velocity and with the participation of Integra Holdings. The company plans to raise a total of $15 million in the financing round. Nectin Therapeutics develops antibodies that inhibit the activity of Nectin family proteins, enhancing the immune systems ability to fight cancers. The investment in Nectin Therapeutics aims to advance and improve the potential of novel immuno-oncology antibodies.
Investment
Nectin Therapeutics Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 11 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
Nectin Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515675890 |
| Crunchbase | nectin-therapeutics |
| Phone | +972544247524 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-05-06T00:00:00.000Z |
| Created | 2018-06-21T00:00:00.000Z |